$EAPH and BMV Medica Announce Eva Pro as Brand Name

The name Eva Pro has been selected by Easton and BMV Medica for its patented women’s diagnostic product that has been licensed from Common Sense Ltd. of Israel who licensed the product to other multinational pharmaceutical companies in the U.S., Canada and Europe. Easton and BMV have begun Trademark registration for the name and are working on completing logo and packaging with unique product names. Pictures can be viewed on BMV’S website athttps://www.bmvmedica.net/en/products/#prettyPhoto/4/

Easton / BMV believe the name is a good representation of the line of products for women who require a professional, patented and certified test able to deliver quick accurate results. In addition, Easton / BMV are near completing discussions to acquire the exclusive licensing rights for the rest of Latin America representing an estimated 400,000,000 population where half are woman and 1 in 3 could use a Point-of -Care vaginal infection test at some point in their lives.

Easton and BMV have entered into an agreement based on a 50 / 50 profit sharing and have begun the process of assembling a World-Class Medical Advisory Board to help guide the Company in the Women’s Health arena. Based on the invaluable knowledge and recommendations from its Medical Advisory Board, Easton/BMV expect a rapid ramp-up in sales once these exclusive diagnostic and treatment options are launched. Additional updates will be disclosed as they become available.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico for patented women’s diagnostic products. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; a company holding Medical Marijuana growing rights in California on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies, a company who own rights to a product called the groZONE anti-microbial airflow system and hold an exclusive option to purchase up to 49% in a (MMPR) medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs and Cannabidiol extracts.

For More Information Visit:
https://www.eastonpharmaceuticalsinc.com
https://ecigmarkets.com
https://finance.yahoo.com/q?s=eaph

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.